Literature DB >> 18201950

Glial cell dysregulation: a new perspective on Alzheimer disease.

Rommy von Bernhardi1.   

Abstract

Alzheimer disease (AD) is a major cause of dementia. Several mechanisms have been postulated to explain its pathogenesis, beta-amyloid (A beta toxicity, cholinergic dysfunction, Tau hyper-phosphorylation, oxidative damage, synaptic dysfunction and inflammation secondary to senile plaques, among others. Glial cells are the major producers of inflammatory mediators, and cytotoxic activation of glial cells is linked to several neurodegenerative diseases; however, whether inflammation is a consequence or the cause of neurodegeneration is still unclear. I propose that inflammation and cellular stress associated with aging are key events in the development of AD through the induction of glial dysfunction. Dysregulated inflammatory response can elicit glial cell activation by compounds which are normally poorly reactive. Inflammation can also be the major cause of defective handling of A beta and the amyloid precursor protein (APP). Here I review evidence that support the proposal that dysfunctional glia and the resulting neuroinflammation can explain many features of AD. Evidence supports the notion that damage caused by inflammation is not only a primary cause of neurodegeneration but also an inducer for the accumulation of A beta in AD. Dysfunctional glia can result in impaired neuronal function in AD, as well as in many progressive neurodegenerative disorders. We show that microglial cell activation is enhanced under pro-inflammatory conditions, indicating that glial cell responses to A beta related proteins can be critically dependent on the priming of glial cells by pro-inflammatory factors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18201950     DOI: 10.1007/bf03033906

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  192 in total

1.  Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

Authors:  D M Walsh; D M Hartley; Y Kusumoto; Y Fezoui; M M Condron; A Lomakin; G B Benedek; D J Selkoe; D B Teplow
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

2.  Phagocytic clearance of apoptotic neurons by Microglia/Brain macrophages in vitro: involvement of lectin-, integrin-, and phosphatidylserine-mediated recognition.

Authors:  A Witting; P Müller; A Herrmann; H Kettenmann; C Nolte
Journal:  J Neurochem       Date:  2000-09       Impact factor: 5.372

3.  Expression of scavenger receptors in glial cells. Comparing the adhesion of astrocytes and microglia from neonatal rats to surface-bound beta-amyloid.

Authors:  Rodrigo Alarcón; Carolina Fuenzalida; Marcos Santibáñez; Rommy von Bernhardi
Journal:  J Biol Chem       Date:  2005-06-29       Impact factor: 5.157

4.  The expression of transforming growth factor-beta1 (TGF-beta1) in hippocampal neurons: a temporary upregulated protein level after transient forebrain ischemia in the rat.

Authors:  Y Zhu; S Roth-Eichhorn; N Braun; C Culmsee; A Rami; J Krieglstein
Journal:  Brain Res       Date:  2000-06-02       Impact factor: 3.252

5.  Amyloid-beta fibril formation is not necessarily required for microglial activation by the peptides.

Authors:  Sadayuki Hashioka; Akira Monji; Tadashi Ueda; Shigenobu Kanba; Hiroshi Nakanishi
Journal:  Neurochem Int       Date:  2005-10       Impact factor: 3.921

6.  Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

Authors:  G P Lim; F Yang; T Chu; P Chen; W Beech; B Teter; T Tran; O Ubeda; K H Ashe; S A Frautschy; G M Cole
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

7.  Inhibition of endotoxin-induced nitric oxide synthase production in microglial cells by the presence of astroglial cells: a role for transforming growth factor beta.

Authors:  V A Vincent; F J Tilders; A M Van Dam
Journal:  Glia       Date:  1997-03       Impact factor: 7.452

8.  Silent brain infarcts and the risk of dementia and cognitive decline.

Authors:  Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

9.  Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase.

Authors:  Magdalena Sastre; Ilse Dewachter; Gary E Landreth; Timothy M Willson; Thomas Klockgether; Fred van Leuven; Michael T Heneka
Journal:  J Neurosci       Date:  2003-10-29       Impact factor: 6.167

10.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

View more
  47 in total

1.  Common key-signals in learning and neurodegeneration: focus on excito-amino acids, beta-amyloid peptides and alpha-synuclein.

Authors:  L F Agnati; G Leo; S Genedani; L Piron; A Rivera; D Guidolin; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2008-11-19       Impact factor: 3.575

Review 2.  Neuroprotective effect of natural products against Alzheimer's disease.

Authors:  Musthafa M Essa; Reshmi K Vijayan; Gloria Castellano-Gonzalez; Mustaq A Memon; Nady Braidy; Gilles J Guillemin
Journal:  Neurochem Res       Date:  2012-05-22       Impact factor: 3.996

3.  Age-dependent changes on TGFβ1 Smad3 pathway modify the pattern of microglial cell activation.

Authors:  Juan E Tichauer; Betsi Flores; Bernardita Soler; Laura Eugenín-von Bernhardi; Gigliola Ramírez; Rommy von Bernhardi
Journal:  Brain Behav Immun       Date:  2013-12-29       Impact factor: 7.217

Review 4.  Microglial priming in Alzheimer's disease.

Authors:  Jun-Wei Li; Yu Zong; Xi-Peng Cao; Lin Tan; Lan Tan
Journal:  Ann Transl Med       Date:  2018-05

Review 5.  Neuroinflammation and microglia: considerations and approaches for neurotoxicity assessment.

Authors:  Gaylia Jean Harry; Andrew D Kraft
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-10       Impact factor: 4.481

Review 6.  Telomere shortening and Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-11-16       Impact factor: 3.843

Review 7.  Role of infection in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  Clive Holmes; Darren Cotterell
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

8.  KCa3.1 constitutes a pharmacological target for astrogliosis associated with Alzheimer's disease.

Authors:  Mengni Yi; Panpan Yu; Qin Lu; Herbert M Geller; Zhihua Yu; Hongzhuan Chen
Journal:  Mol Cell Neurosci       Date:  2016-08-24       Impact factor: 4.314

9.  Microglia in the aging brain: relevance to neurodegeneration.

Authors:  Xiao-Guang Luo; Jian-Qing Ding; Sheng-Di Chen
Journal:  Mol Neurodegener       Date:  2010-03-24       Impact factor: 14.195

10.  Pristimerin Inhibits LPS-Triggered Neurotoxicity in BV-2 Microglia Cells Through Modulating IRAK1/TRAF6/TAK1-Mediated NF-κB and AP-1 Signaling Pathways In Vitro.

Authors:  Bin Hui; Liping Zhang; Qinhua Zhou; Ling Hui
Journal:  Neurotox Res       Date:  2017-11-08       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.